221 related articles for article (PubMed ID: 33444080)
1. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.
Magnuson A; Sedrak MS; Gross CP; Tew WP; Klepin HD; Wildes TM; Muss HB; Dotan E; Freedman RA; O'Connor T; Dale W; Cohen HJ; Katheria V; Arsenyan A; Levi A; Kim H; Mohile S; Hurria A; Sun CL
J Clin Oncol; 2021 Feb; 39(6):608-618. PubMed ID: 33444080
[TBL] [Abstract][Full Text] [Related]
2. Predicting chemotherapy toxicity in older adults: Comparing the predictive value of the CARG Toxicity Score with oncologists' estimates of toxicity based on clinical judgement.
Moth EB; Kiely BE; Stefanic N; Naganathan V; Martin A; Grimison P; Stockler MR; Beale P; Blinman P
J Geriatr Oncol; 2019 Mar; 10(2):202-209. PubMed ID: 30224184
[TBL] [Abstract][Full Text] [Related]
3. Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.
Ji J; Bae M; Sun CL; Wildes TM; Freedman RA; Magnuson A; O'Connor T; Moy B; Klepin HD; Chapman AE; Tew WP; Dotan E; Fenton MA; Kim H; Katheria V; Gross CP; Cohen HJ; Muss HB; Sedrak MS
Cancer; 2024 Mar; 130(6):936-946. PubMed ID: 37962093
[TBL] [Abstract][Full Text] [Related]
4. Toxicity risk score and clinical decline after adjuvant chemotherapy in older breast cancer survivors.
Ji J; Sun CL; Cohen HJ; Muss HB; Bae M; Sedrak MS
J Natl Cancer Inst; 2023 May; 115(5):578-585. PubMed ID: 36762832
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.
Nyrop KA; Deal AM; Shachar SS; Basch E; Reeve BB; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Reeder-Hayes KE; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Oncologist; 2019 Jun; 24(6):762-771. PubMed ID: 30552158
[TBL] [Abstract][Full Text] [Related]
6. Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer.
Cavdar E; Iriagac Y; Karaboyun K; Avci O; Seber ES
J Geriatr Oncol; 2022 Jul; 13(6):821-827. PubMed ID: 35361561
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the CARG tool, the VES-13, and oncologist judgment in predicting grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer.
Alibhai SM; Aziz S; Manokumar T; Timilshina N; Breunis H
J Geriatr Oncol; 2017 Jan; 8(1):31-36. PubMed ID: 27756545
[TBL] [Abstract][Full Text] [Related]
8. Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study.
Ostwal V; Ramaswamy A; Bhargava P; Hatkhambkar T; Swami R; Rastogi S; Mandavkar S; Ghosh J; Bajpai J; Gulia S; Srinivas S; Rath S; Gupta S
BMJ Open; 2021 Jun; 11(6):e047376. PubMed ID: 34187825
[TBL] [Abstract][Full Text] [Related]
9. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.
Hurria A; Togawa K; Mohile SG; Owusu C; Klepin HD; Gross CP; Lichtman SM; Gajra A; Bhatia S; Katheria V; Klapper S; Hansen K; Ramani R; Lachs M; Wong FL; Tew WP
J Clin Oncol; 2011 Sep; 29(25):3457-65. PubMed ID: 21810685
[TBL] [Abstract][Full Text] [Related]
10. Acute toxicity and tolerability of anthracycline-based chemotherapy regimens in older versus younger patients with breast cancer: real-world data.
Monteiro AR; Garcia AR; Póvoa S; Soares RF; Macedo F; Pereira TC; Domingues I; Pazos I; Sousa G
Support Care Cancer; 2021 May; 29(5):2347-2353. PubMed ID: 32918130
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer.
Zauderer M; Patil S; Hurria A
Breast Cancer Res Treat; 2009 Sep; 117(1):205-10. PubMed ID: 18622739
[TBL] [Abstract][Full Text] [Related]
13. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
14. External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort.
Frelaut M; Paillaud E; Beinse G; Scain AL; Culine S; Tournigand C; Poisson J; Bastuji-Garin S; Canoui-Poitrine F; Caillet P
Oncologist; 2023 Jun; 28(6):e341-e349. PubMed ID: 37027521
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer.
Mariano C; Lund JL; Peacock Hinton S; Htoo P; Muss H; Reeder-Hayes KE
J Geriatr Oncol; 2017 Jul; 8(4):242-248. PubMed ID: 28601373
[TBL] [Abstract][Full Text] [Related]
16. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
Hurria A; Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Howard J; Hudis C
Drugs Aging; 2005; 22(9):785-91. PubMed ID: 16156682
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study.
Hou N; Xiao J; Wang Z; Wu Y; Hou G; Guo L; Zhang J; Ling R
Clin Breast Cancer; 2020 Dec; 20(6):e682-e694. PubMed ID: 32713825
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
